October 1, 2024 11:30 AM EDT
News Briefing

Bio­haven aims to raise $250M; Ac­tivist in­vestor's stake in Gala­pa­gos ex­ceeds 10%

ENDPOINTS

Plus, news about IN8bio, Sanofi, Vi­core Phar­ma, Carther­ics, Zephyrm Bio­science, Tharim­mune and In­tract Phar­ma:

Bio­haven’s $250M of­fer­ing: The move comes af­ter Bio­haven an­nounced Mon­day that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times